6 Biotechnology Stocks to Buy Now

Advertisement

Six biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

This week, La Jolla Pharmaceutical Company (LJPC) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, LJPC also gets A’s. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

This week, Incyte Corporation (INCY) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.

Ambit Biosciences Corp. (AMBI) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Progenics Pharmaceuticals, Inc. (PGNX) is seeing ratings go up from a C last week to a B this week. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

Celladon Corporation (CLDN) boosts its rating from a B to an A this week. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of CLDN stock.

The rating of Pfenex Inc (PFNX) moves up this week, rising from a B to an A. For more information, get Portfolio Grader’s complete analysis of PFNX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/08/6-biotechnology-stocks-to-buy-now-ljpc-incy-ambi-4/.

©2024 InvestorPlace Media, LLC